Show Summary Details
Page of

Therapeutics 

Therapeutics
Chapter:
Therapeutics
Author(s):

Dafna D. Gladman

, Cheryl F. Rosen

, and Vinod Chandran

DOI:
10.1093/med/9780199692095.003.0009
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 30 May 2020

Therapy of psoriatic arthritis is best managed in an interprofessional environment due to the various manifestations that transcend traditional specialty boundaries

There are few clinical trials conducted with traditional DMARDs in PsA; evidence to date have not shown significant benefit for joint disease

Anti-TNF agents are effective in the management of all manifestations of psoriatic arthritis

There are few options in patients who fail anti-TNF therapy

GRAPPA recommends that the worst individual domain among the five domains should guide the choice of therapeutic agents in the management of PsA

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.